Skip to main content
. 2016 May 31;7(26):40314–40328. doi: 10.18632/oncotarget.9739

Figure 4. miR-337-3p suppresses the growth, invasion, and angiogenesis of gastric cancer cells through repressing MZF1-facilitated MMP-14 expression in vitro.

Figure 4

(A and B), western blot and dual-luciferase assays showing the expression of MZF1 and MMP-14 and promoter activity of MMP-14 in MKN-45 and SGC-7901 cells stably transfected with empty vector (mock) or miR-337-3p precursor, and those co-transfected with MZF1. (C), ChIP and qPCR assay indicating the enrichment of MZF1 on MMP-14 promoter in gastric cancer cells stably transfected with mock or miR-337-3p precursor, and those co-transfected with MZF1. (D), representation (left) and quantification (right) of soft agar assay showing the anchorage-independent growth of MKN-45 and SGC-7901 cells stably transfected with mock or miR-337-3p precursor, and those co-transfected with MZF1. (E), representation (left) and quantification (right) of matrigel invasion assay indicating the invasion capability of gastric cancer cells stably transfected with mock or miR-337-3p precursor, and those co-transfected with MZF1. (F), representation (left) and quantification (right) of tube formation assay showing the angiogenic capability of gastric cancer cells stably transfected with mock or miR-337-3p precursor, and those co-transfected with MZF1. *P < 0.01 vs. mock.